Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by barcodewhizon Jun 02, 2006 12:50pm
160 Views
Post# 10938455

financing

financing So here's the financing as we predicted. Now the $200 million dollar question is... how good are these 1402 results going to be ? I must say I am VERY ENCOURAGED at the fact that this was stickhandles by JP Morgan and not another US Rape and Pillage Bucket shop. I actually have to give Nicole credit on this one... I believe she specifically forged a relationship with the JP Morgan analyst that covers PALL... which has led to Morgan taking an interest in Prometic's prospect. Getting Morgan supporting this stock to their institutional clients is the kind of thing that could seriously change the fortunes of this company..... especially if we make the planned headway with MacoPharma and 1402 results... What's bothered me for a long time is the fact that we lost the attention of the institutional market. I was legitimately worried that there was no one waiting to buy good news. I like this deal... and I feel better about the next two quarters.. I think the risk / reward just got that much better. If we get decent 1402 news... then we are legitimately off to the races... Morgan and their clients are the kinds of people that pay attention to the Fibrogen deal and understand how to bring parties together to create value.... we arent out of the woods.. but this is a great step forward.
Bullboard Posts